|
Video: What is a Stock Split?
|
|
Synaptogenix is a biopharmaceutical company. Co. is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Co. is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing. Co. has completed an additional analysis in connection with the confirmatory Phase 2 study, which examined moderately severe to severe AD patients treated with Bryostatin-1 in the absence of memantine. According to our SNPX split history records, Synaptogenix has had 1 split. | |
|
Synaptogenix (SNPX) has 1 split in our SNPX split history database. The split for SNPX took place on April 05, 2024. This was a 1 for 25 reverse split, meaning for each 25 shares of SNPX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split.
When a company such as Synaptogenix conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the SNPX split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Synaptogenix shares, starting with a $10,000 purchase of SNPX, presented on a split-history-adjusted basis factoring in the complete SNPX split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/06/2021 |
|
End date: |
04/30/2024 |
|
Start price/share: |
$40.00 |
|
End price/share: |
$4.74 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-88.15% |
|
Average Annual Total Return: |
-47.48% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,184.74 |
|
Years: |
3.31 |
|
|
|
Date |
Ratio |
04/05/2024 | 1 for 25 |
|
|